{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:29:26Z","timestamp":1777433366013,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T00:00:00Z","timestamp":1153785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T00:00:00Z","timestamp":1153785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1007\/s00259-006-0150-2","type":"journal-article","created":{"date-parts":[[2006,7,24]],"date-time":"2006-07-24T13:00:55Z","timestamp":1153746055000},"page":"1387-1398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":275,"title":["[18F]fluorocholine PET\/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients"],"prefix":"10.1007","volume":"33","author":[{"given":"Marino","family":"Cimitan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bortolus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Morassut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Canzonieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Garbeglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Baresic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Borsatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Drigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro G.","family":"Trov\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,7,25]]},"reference":[{"key":"150_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1023\/A:1015531326689","volume":"20","author":"G Buchanan","year":"2001","unstructured":"Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20:207\u2013223","journal-title":"Cancer Metastasis Rev"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1200\/JCO.2004.04.579","volume":"22","author":"A Loblaw","year":"2004","unstructured":"Loblaw A, Mendelson D, Talcott J, Virgo K, Somerfield M, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927\u20132941","journal-title":"J Clin Oncol"},{"key":"150_CR3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0094-0143(21)01389-6","volume":"18","author":"JM Kozlowski","year":"1991","unstructured":"Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am 1991;18:15\u201324","journal-title":"Urol Clin North Am"},{"key":"150_CR4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cncr.1990.66.s5.1009","volume":"66","author":"PH Smith","year":"1990","unstructured":"Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A sub analysis of EORTC trial 30853. The EORTC Urological Group. Cancer 1990;66:1009\u20131016","journal-title":"Cancer"},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0090-4295(96)00250-6","volume":"48","author":"F Parivar","year":"1996","unstructured":"Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996;48:594\u2013599","journal-title":"Urology"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0033-8389(05)70150-0","volume":"38","author":"KK Yu","year":"2000","unstructured":"Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38:59\u201385","journal-title":"Radiol Clin North Am"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0033-8389(05)70152-4","volume":"38","author":"J Kurhanewicz","year":"2000","unstructured":"Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000;38:115\u2013138","journal-title":"Radiol Clin North Am"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0033-8389(05)70157-3","volume":"38","author":"DM Nudell","year":"2000","unstructured":"Nudell DM, Wefer AE, Hricak H, Caroll PR. Imaging for recurrent prostate cancer. Radiol Clin North Am 2000;38:213\u2013229","journal-title":"Radiol Clin North Am"},{"key":"150_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1046\/j.1464-410x.2001.00018.x","volume":"87","author":"F May","year":"2001","unstructured":"May F, Treumann T, Dettmar P, Hartung R, Breul J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 2001;87:66\u201369","journal-title":"BJU Int"},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S0093-7754(03)00359-2","volume":"30","author":"H Hricak","year":"2003","unstructured":"Hricak H, Schoder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, et al. Advances in imaging in the postoperative patients with a rising prostate-specific antigen level. Semin Oncol 2003;30:616\u2013634","journal-title":"Semin Oncol"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0022-5347(01)63239-7","volume":"159","author":"D Kahn","year":"1998","unstructured":"Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, et al. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Group. J Urol 1998;159:2041\u20132046","journal-title":"J Urol"},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0022-5347(01)62545-X","volume":"160","author":"M Cher","year":"1998","unstructured":"Cher M, Bianco F Jr, Lam J, Davis L, Grignon D, Sakr W, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387\u20131391","journal-title":"J Urol"},{"key":"150_CR13","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/S0022-5347(05)67511-8","volume":"163","author":"JW Moul","year":"2000","unstructured":"Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632\u20131642","journal-title":"J Urol"},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4065\/76.6.576","volume":"76","author":"SG Roberts","year":"2001","unstructured":"Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576\u2013581","journal-title":"Mayo Clin Proc"},{"key":"150_CR15","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1200\/JCO.2005.06.058","volume":"23","author":"Z Dotan","year":"2005","unstructured":"Dotan Z, Bianco F, Rabbani F, Easthman J, Fearn P, Scher H, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23:1962\u20131968","journal-title":"J Clin Oncol"},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0022-5347(01)63916-8","volume":"159","author":"CK Hoh","year":"1998","unstructured":"Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrum A. Positron emission tomography in urological oncology. J Urol 1998;159:347\u2013356","journal-title":"J Urol"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000019923","volume":"36","author":"C Hofer","year":"1999","unstructured":"Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31\u201335","journal-title":"Eur Urol"},{"key":"150_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0090-4295(00)00896-7","volume":"57","author":"IJ Liu","year":"2001","unstructured":"Liu IJ, Zafar MB, Lai YH, Segall GM, Terri MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108\u2013111","journal-title":"Urology"},{"key":"150_CR19","first-page":"990","volume":"39","author":"T Hara","year":"1998","unstructured":"Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990\u2013995","journal-title":"J Nucl Med"},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s002590000309","volume":"27","author":"J Kotzerke","year":"2000","unstructured":"Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinshmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27;1415\u20131419","journal-title":"Eur J Nucl Med"},{"key":"150_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0302-2838(02)00129-X","volume":"42","author":"IJ De Jong","year":"2002","unstructured":"De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002;42:18\u201323","journal-title":"Eur Urol"},{"key":"150_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1095-0397(00)00059-5","volume":"3","author":"R Coleman","year":"2000","unstructured":"Coleman R, De Grado T, Wang S, Baldwin S, Orr M, Reiman R, et al. Preliminary evaluation of F-18 Fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000;3:147","journal-title":"Clin Positron Imaging"},{"key":"150_CR23","first-page":"549","volume":"44","author":"N Oyama","year":"2003","unstructured":"Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549\u2013555","journal-title":"J Nucl Med"},{"key":"150_CR24","first-page":"110","volume":"61","author":"T De Grado","year":"2001","unstructured":"De Grado T, Coleman R, Wang S, Baldwin S, Orr M, Robertson C, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110\u2013117","journal-title":"Cancer Res"},{"key":"150_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1053\/j.semnuclmed.2004.06.004","volume":"34","author":"H Schoder","year":"2004","unstructured":"Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274\u2013292","journal-title":"Semin Nucl Med"},{"key":"150_CR26","first-page":"1233","volume":"45","author":"M Seltzer","year":"2004","unstructured":"Seltzer M, Jahan S, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, et al. Radiation dose estimates in humans for 11C-acetate whole-body PET. J Nucl Med 2004;45:1233\u20131236","journal-title":"J Nucl Med"},{"key":"150_CR27","first-page":"92","volume":"43","author":"T De Grado","year":"2002","unstructured":"De Grado T, Reiman R, Price D, Wang S, Coleman R. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002;43:92\u201396","journal-title":"J Nucl Med"},{"key":"150_CR28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1148\/radiol.2352040494","volume":"235","author":"D Schmid","year":"2005","unstructured":"Schmid D, John H, Zweifel R, Cservenyak T, Westera G, Goerres G, et al. Fluorocholine PET\/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623\u2013628","journal-title":"Radiology"},{"key":"150_CR29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/01.ju.0000056901.95996.43","volume":"169","author":"M Picchio","year":"2003","unstructured":"Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337\u20131340","journal-title":"J Urol"},{"key":"150_CR30","first-page":"331","volume":"44","author":"IJ De Jong","year":"2003","unstructured":"De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331\u2013335","journal-title":"J Nucl Med"},{"key":"150_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0302-2838(03)00207-0","volume":"44","author":"IJ De Jong","year":"2003","unstructured":"De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32\u201339","journal-title":"Eur Urol"},{"key":"150_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00259-003-1377-9","volume":"31","author":"E Sutinen","year":"2004","unstructured":"Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317\u2013324","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"150_CR33","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00259-004-1755-y","volume":"32","author":"T Yamaguchi","year":"2005","unstructured":"Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005;32:742\u2013748","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"150_CR34","first-page":"1642","volume":"46","author":"M Farsad","year":"2005","unstructured":"Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of 11C-choline PET\/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642\u20131649","journal-title":"J Nucl Med"},{"issue":"suppl","key":"150_CR35","first-page":"44P","volume":"38","author":"T Hara","year":"1997","unstructured":"Hara T, Yuasa M. Automated synthesis of fluorine-18 labeled choline analogue: 2-fluoroethyl-dimethyl-2oxyethylammonium [abstract]. J Nucl Med 1997;38(suppl):44P","journal-title":"J Nucl Med"},{"key":"150_CR36","first-page":"187","volume":"43","author":"T Hara","year":"2002","unstructured":"Hara T, Kosaka N, Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187\u2013199","journal-title":"J Nucl Med"},{"key":"150_CR37","first-page":"1805","volume":"42","author":"T De Grado","year":"2001","unstructured":"De Grado T, Baldwin R, Wang S, Orr M, Liao R, Friedman H, et al. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805\u20131814","journal-title":"J Nucl Med"},{"key":"150_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0022-5347(05)64906-3","volume":"168","author":"D Price","year":"2002","unstructured":"Price D, Coleman R, Liao R, Robertson C, Polascik T, De Grado T. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273\u2013280","journal-title":"J Urol"},{"key":"150_CR39","first-page":"262","volume":"47","author":"S Kwee","year":"2006","unstructured":"Kwee S, Wei H, Sesterhenn I, Yun D, Coel M. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006;47:262\u2013269","journal-title":"J Nucl Med"},{"key":"150_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0090-4295(02)02268-9","volume":"61","author":"S Freedland","year":"2003","unstructured":"Freedland S, Sutter M, Dorey F, Aronson W. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy: prostate-specific antigen. Urology 2003;61:365\u2013369","journal-title":"Urology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-006-0150-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-006-0150-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-006-0150-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-006-0150-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T23:07:59Z","timestamp":1652569679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-006-0150-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,25]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s00259-006-0150-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,25]]},"assertion":[{"value":"15 February 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}